India, May 1 -- Shares of Arvinas, Inc. (ARVN) experienced a significant decline on Thursday morning, with its stock price dropping over 27%. The downturn follows the release of results from the company's Phase 3 VERITAC-2 trial for its breast cancer drug candidate, vepdegestrant, as well as financial results for the first quarter.
ARVN is currently trading at $6.99, down $2.62 or 27.29%, on the Nasdaq. The stock opened its trading at $6.37 after closing Wednesday at $9.62. The stock has traded between $5.94 and $37.38 in the past 52-week period.
The company reported positive topline data for VERITAC-2, the Phase 3 pivotal 2L+ trial of monotherapy vepdegestrant in patients with estrogen receptor-positive, human epidermal growth factor rec...